Abstract
Purpose
In order to identify the impact of local treatment on overall survival (OS) and cancer-specific
survival(CSS) in men with mPCa.
Materials and methods
Men with mPCa undergoing local treatment by radical prostatectomy (RP), radiotherapy
(RT) including beam radiation and brachytherapy or no local treatment identified from
Surveillance, Epidemiology, and End Results (SEER) database (2010–2015). To evaluate
local therapy impact on OS and CSS in relation to baseline characteristics, univariate
and multivariable Cox regression analysis was used to predict the prognostic value
of local therapy in OS and CSS.
Results
A total of 902(25.8%) patients received local treatment and 2598(74.2%) patients did
not receive local treatment in this study. The Kaplan-Meier curves showed that there
was significant difference in OS between patients underwent local treatment and patients
without local treatment (p=0.013) but not in CSS (p=0.068). While multivariate Cox
regression analysis showed that local treatment may not significantly improve OS(p=0.724).
In subgroup analysis, Among patients with prostate-specific antigent (PSA)<10ng/ml,
local treatment could significantly improve OS and CSS (all p<0.05). Multivariate
Cox regression analysis showed that local treatment could be used as an independent
prognostic factor to improve OS in mPCa patients with PSA<10ng/ml (p=0.031). Another
multivariate Cox regression analysis demonstrated that patients with mPCa undergoing
RP had better OS and CSS (all p<0.05).
Conclusions
Our results showed that local salvage therapy did not seem to be an independent prognostic
factor in all mPCa patients, but we found that local therapy can show a better prognosis
in patients with lower PSA levels. Compared with RT, patients who had experienced
RP may have better prognosis. We still need prospective research to further study
the application value of local treatment in mPCa patients
MicroAbstract
local treatment may not effectively improve the prognosis of mPCa patients. Patients
with low level PSA underwent local treatment had better OS. Compared with RT, RP could
effectively improve the prognosis of mPCa patients.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Reference
- Cancer Statistics, 2021[J].CA: a cancer journal for clinicians. 2021; 71: 7-33
- The National Prostate Cancer Audit – Results from the Organisational Survey of NHS Trusts in England[J].Clinical Oncology. 2015; 27: e3
- Management of Prostate Cancer[J].Journal of the National Comprehensive Cancer Network: JNCCN. 2019; 17: 583-586
- Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial[J].The Lancet. 2018; 392: 2353-2366
- TESTING RADICAL PROSTATECTOMY IN MEN WITH OLIGOMETASTATIC PROSTATE CANCER THAT HAS SPREAD TO THE BONE- A RANDOMIZED CONTROLLED FEASIBILITY TRIAL[J].The Journal of Urology. 2019; 201 (Supplement 4)
- Cytoreductive Radical Prostatectomy in Patients with Prostate Cancer and Low Volume Skeletal Metastases: Results of a Feasibility and Case-Control Study[J].Journal of Urology. 2015; 193: 832-838
- Tumor-derived exosomes promote tumor self-seeding in hepatocellular carcinoma by transferring miRNA-25-5p to enhance cell motility[J].Oncogene. 2018;
- Tumor Self-Seeding by Circulating Cancer Cells[J].Cell. 2009; 139: 1315
- Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis[J].Journal of Urology. 2015; 194: 378-385
- The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis[J].European Urology. 2017; 72: 14-19
- Identifying Optimal Candidates for Local Treatment of the Primary Tumor Among Patients Diagnosed with Metastatic Prostate Cancer: A SEER-based Study[J].European Urology. 2015; 67: 3-6
- Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis[J].F1000 Research. 2018; 7: 246
- Local treatment of metastatic cancer–killing the seed or disturbing the soil?[J].Nature reviews. Clinical oncology. 2011; 8: 504-506
- VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche[J].Nature. 2005; 438: 820-827
- Mechanisms Governing Metastatic Dormancy and Reactivation[J].Cell. 2013; 155: 750-764
- Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study[J].European Urology Focus. 2017; 3: 646-649
- Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer[J].PROSTATE. 2017;
- Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer[J].Journal of Clinical Oncology. 2016; 34: 2835-2842
- Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial[J].European Urology. 2019; 75: 410-418
- Standard systemic therapy with or without defifinitive treatment in treating participants with metastatic prostate cancer: US National Library of Medicine Clinical Trials.gov. 2018; (Available at) (Accessed January 2020)
Article info
Publication history
Accepted:
January 15,
2023
Received in revised form:
January 11,
2023
Received:
February 7,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Published by Elsevier Inc.
